


PRODUCT INFORMATION



Cannabidiol (exempt preparation)

Item No. 90081

CAS Registry No.: 13956-29-1
Formal Name: 2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol
Synonym: CBD
MF: C₂₁H₃₀O₂
FW: 314.5
Purity: ≥99%
Stability: ≥1 year at -20°C
Supplied as: A solution in methanol
UV/Vis.: λ_{max}: 209, 275 nm



Laboratory Procedures

For long term storage, we suggest that cannabidiol (exempt preparation) be stored as supplied at -20°C. It should be stable for at least one year.

Cannabidiol (exempt preparation) is supplied as a solution in methanol. To change the solvent, simply evaporate the methanol under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as ethanol, methanol, DMSO, and dimethyl formamide purged with an inert gas can be used. The solubility of cannabidiol (exempt preparation) in these solvents is approximately 35, 30, 60, and 50 mg/ml, respectively.

Cannabidiol (exempt preparation) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, cannabidiol (exempt preparation) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Cannabidiol (exempt preparation) has a solubility of 250 µg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Cannabidiol is an active phytocannabinoid identified in *Cannabis* (composes ~40% of the plant's extract). Unlike Δ⁹-THC (Item No. 12068), cannabidiol is considered to be non-psychoactive.¹ Cannabidiol has a very low affinity for CB₁ and CB₂ receptors but acts as an indirect antagonist and is thought to potentiate the effects of Δ⁹-THC.² Cannabidiol is reported to act as a CB₂ receptor inverse agonist, GPR55 antagonist, and a 5-HT_{1A} receptor agonist.²⁻⁵ It can allosterically modulate μ- and δ-opioid receptors as well as agonize PPARγ receptors and stimulate intracellular calcium release.^{6,7}

References

1. Kozela, E., Juknat, A., Kaushansky, N., et al. *J. Neuroinflamm.* **12**(52), (2015).
2. Mechoulam, R., Peters, M., Murillo-Rodriguez, E., et al. *Chem. Biodivers.* **4**, 1678-1692 (2007).
3. Pertwee, R.G. *Br. J. Pharmacol.* **153**(2), 199-215 (2008).
4. Ryberg, E., Larsson, N., Sjögren, S., et al. *Br. J. Pharmacol.* **152**, 1092-1101 (2007).
5. Russo, E.B., Burnett, A., Hall, B., et al. *Neurochem. Res.* **30**(8), 1037-1043 (2005).
6. Campos, A.C., Moreira, F.A., Gomes, F.V., et al. *Phil. Trans. R. Soc. B.* **367**, 3364-3378 (2012).
7. Kathmann, M., Flau, K., Redmer, A., et al. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **372**(5), 354-361 (2006).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/17/2015

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM